Astellas is still struggling to close its $379M Ocata buyout

Damian Garde When Astellas signed a deal to acquire Ocata Therapeutics in November, it expected the company's shareholders to accept its $ 8.50-a-share offer within 20 days. But ...

Actelion CEO dismisses talk of Basilea buyout bid

Nick Paul Taylor Actelion CEO Jean-Paul Clozel has dismissed the possibility of making a bid to buy Basilea Pharmaceutica. The comment quashed speculation that Actelion and Basilea ...

Medicines Co. jumps on rumors of a multibillion-dollar buyout

Damian Garde Drugmaker the Medicines Company saw its shares rise as high as 14% on rumors that the company may be up for sale. FierceBiotech News

Acorda bags PhIII Parkinson’s drug in $363M Biotie buyout

John Carroll FierceBiotech News

UPDATED: Shire finally gets it done, bagging Baxalta in $32B buyout

John Carroll It took a few months, but Shire has wrapped a $ 32 billion deal to acquire Baxalta, providing CEO Flemming Ornskov with the big merger that he has been promising investors. FierceBiotech ...

UPDATED: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report

John Carroll Four days after Acerta Pharma quietly posted some promising early-stage data on its Bruton's tyrosine kinase (Btk) inhibitor acalabrutinib, AstraZeneca has popped up ...

Allergan plots 117 job cuts in the wake of Kythera buyout

Tracy Staton The job-cutting ax has been hovering over Kythera Biopharmaceuticals ever since Allergan agreed to buy the company in April. Now, that ax is getting ready to fall. FiercePharma ...

LimmaTech sets up as de facto GSK vaccine R&D unit in wake of $190M buyout

Nick Paul Taylor LimmaTech Biologics, a spillover from the $ 190 million (€169 million) takeover of GlycoVaxyn by GlaxoSmithKline, has opened its doors. The biotech is starting ...

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

John Carroll Shire has been quiet since making its unwelcomed $ 30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step ...

Perrigo CEO: Think Mylan’s buyout will come easily? Think again

Carly Helfand Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan's generics business for $ 40.5 billion. Mylan's ...

Baxalta to Shire: We’re young, we’re just starting to grow, and we’re rejecting your buyout offer

Carly Helfand On Tuesday, Shire went public with a $ 30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's ...

UPDATED: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout

John Carroll The big news in biopharma this weekend is the unconfirmed report that Allergan is looking to sell its generics business to Teva. But Allergan execs didn't let the headlines ...
Page 1 of 712345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS